The Chemical Inhibitors of Endocytosis: From Mechanisms to Potential Clinical Applications

Olga Klaudia Szewczyk-Roszczenko; Piotr Roszczenko; Anna Shmakova; Nataliya Finiuk; Serhii Holota; Roman Lesyk; Anna Bielawska; Yegor Vassetzky; Krzysztof Bielawski

doi:10.3390/cells12182312

The Chemical Inhibitors of Endocytosis: From Mechanisms to Potential Clinical Applications

Cells. 2023 Sep 19;12(18):2312. doi: 10.3390/cells12182312.

Authors

Olga Klaudia Szewczyk-Roszczenko¹, Piotr Roszczenko², Anna Shmakova³, Nataliya Finiuk⁴, Serhii Holota⁵, Roman Lesyk⁵, Anna Bielawska², Yegor Vassetzky³, Krzysztof Bielawski¹

Affiliations

¹ Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
² Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
³ CNRS, UMR 9018, Institut Gustave Roussy, Université Paris-Saclay, 94800 Villejuif, France.
⁴ Department of Regulation of Cell Proliferation and Apoptosis, Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov 14/16, 79005 Lviv, Ukraine.
⁵ Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.

Abstract

Endocytosis is one of the major ways cells communicate with their environment. This process is frequently hijacked by pathogens. Endocytosis also participates in the oncogenic transformation. Here, we review the approaches to inhibit endocytosis, discuss chemical inhibitors of this process, and discuss potential clinical applications of the endocytosis inhibitors.

Keywords: cell-penetrating peptides; clathrin-independent endocytosis; clathrin-mediated endocytosis; inhibitors of endocytosis.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Endocytosis* / drug effects

Grants and funding

This work was funded by the ANRS and SFCE (France), the Polish National Agency for Academic Exchange under the Strategic Partnerships program (grant agreement no. BPI/PST/2021/1/00002/U/00001), and the Medical University of Bialystok, grant No. B.SUB.23.156. Travel between partner labs was funded by the AMORCE and ERASMUS programs.